<antigenSupportingData>
<immunity>
</immunity>
<contraindications>
<vaccineGroup>
<contraindication>
<observationCode>122</observationCode>
<observationTitle>Severe allergic reaction after previous dose of COVID-19</observationTitle>
<contraindicationText>Do not vaccinate if the patient has had a severe allergic reaction after a previous dose of COVID-19 vaccine.</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
<contraindication>
<observationCode>080</observationCode>
<observationTitle>Adverse reaction to vaccine component</observationTitle>
<contraindicationText>Do not vaccinate if the patient has had an adverse reaction to a vaccine component.</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
</vaccineGroup>
<vaccine>
<contraindication>
<observationCode>187</observationCode>
<observationTitle>Allergic reaction to polysorbate 80</observationTitle>
<contraindicationText>Do not vaccinate if the patient has had an immediate allergic reaction of any severity to polysorbate 80.</contraindicationText>
<contraindicationGuidance/>
<contraindicatedVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge/>
<endAge/>
</contraindicatedVaccine>
</contraindication>
<contraindication>
<observationCode>188</observationCode>
<observationTitle>Known allergy to Polyethylene glycol [PEG]</observationTitle>
<contraindicationText>Do not vaccinate if the patient has known allergy to Polyethylene glycol [PEG].</contraindicationText>
<contraindicationGuidance/>
<contraindicatedVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge/>
<endAge/>
</contraindicatedVaccine>
<contraindicatedVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge/>
<endAge/>
</contraindicatedVaccine>
</contraindication>
</vaccine>
</contraindications>
<series>
<seriesName>2-dose Pfizer series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Current evidence suggests that the risk of SARS-CoV-2 reinfection is low in the months after initial infection but may increase with time due to waning immunity. Thus, people with a history of MIS-C or MIS-A should consider delaying vaccination until they have recovered from illness and for 90 days after the date of diagnosis of MIS-C or MIS-A, recognizing that the risk of reinfection and, therefore, the benefit from vaccination, might increase with time following initial infection.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesType>Standard</seriesType>
<equivalentSeriesGroups>2; 3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>Yes</defaultSeries>
<productPath>Yes</productPath>
<seriesGroupName>Standard</seriesGroupName>
<seriesGroup>1</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>1</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication/>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>21 days - 4 days</absMinInt>
<minInt>21 days</minInt>
<earliestRecInt>21 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>Y</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>2-dose Moderna series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Current evidence suggests that the risk of SARS-CoV-2 reinfection is low in the months after initial infection but may increase with time due to waning immunity. Thus, people with a history of MIS-C or MIS-A should consider delaying vaccination until they have recovered from illness and for 90 days after the date of diagnosis of MIS-C or MIS-A, recognizing that the risk of reinfection and, therefore, the benefit from vaccination, might increase with time following initial infection.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesAdminGuidance>If age 12 through 17 years and Moderna vaccine inadvertently administered instead of Pfizer-BioNTech as the first dose, may administer Moderna vaccine as the second dose (as off-label use, because Moderna vaccine is not authorized in this age group).</seriesAdminGuidance>
<seriesType>Standard</seriesType>
<equivalentSeriesGroups>2; 3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>Yes</productPath>
<seriesGroupName>Standard</seriesGroupName>
<seriesGroup>1</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>2</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication/>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>208; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>208; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>28 days - 4 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>Y</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>1-dose Janssen series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Current evidence suggests that the risk of SARS-CoV-2 reinfection is low in the months after initial infection but may increase with time due to waning immunity. Thus, people with a history of MIS-C or MIS-A should consider delaying vaccination until they have recovered from illness and for 90 days after the date of diagnosis of MIS-C or MIS-A, recognizing that the risk of reinfection and, therefore, the benefit from vaccination, might increase with time following initial infection.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesType>Standard</seriesType>
<equivalentSeriesGroups>2; 3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>Yes</productPath>
<seriesGroupName>Standard</seriesGroupName>
<seriesGroup>1</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>3</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication/>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 208; 210; 211; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>2-dose mRNA series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Current evidence suggests that the risk of SARS-CoV-2 reinfection is low in the months after initial infection but may increase with time due to waning immunity. Thus, people with a history of MIS-C or MIS-A should consider delaying vaccination until they have recovered from illness and for 90 days after the date of diagnosis of MIS-C or MIS-A, recognizing that the risk of reinfection and, therefore, the benefit from vaccination, might increase with time following initial infection.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesType>Standard</seriesType>
<equivalentSeriesGroups>2; 3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>No</productPath>
<seriesGroupName>Standard</seriesGroupName>
<seriesGroup>1</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>4</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication/>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>210; 211; 212</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge/>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>210; 211; 212</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>28 days - 4 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>Risk 3-dose Pfizer series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>A patients clinical team is best positioned to determine the degree of immune compromise and appropriate timing of vaccination.

Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.</seriesAdminGuidance>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Current evidence suggests that the risk of SARS-CoV-2 reinfection is low in the months after initial infection but may increase with time due to waning immunity. Thus, people with a history of MIS-C or MIS-A should consider delaying vaccination until they have recovered from illness and for 90 days after the date of diagnosis of MIS-C or MIS-A, recognizing that the risk of reinfection and, therefore, the benefit from vaccination, might increase with time following initial infection.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesType>Risk</seriesType>
<equivalentSeriesGroups>3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>Yes</defaultSeries>
<productPath>Yes</productPath>
<seriesGroupName>Increased Risk</seriesGroupName>
<seriesGroup>2</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>1</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication>
<observationCode>
<text>Recipient of a hematopoietic stem cell transplant</text>
<code>004</code>
</observationCode>
<description>Administer to recipients of a hematopoietic stem cell transplant [HSCT] within 2 years of successful transplantation.</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>B-lymphocyte [humoral] - Severe antibody deficiencies</text>
<code>145</code>
</observationCode>
<description>Administer to persons who have severe B-lymphocyte (humoral) - antibody deficiencies (e.g., X-linked agammaglobulinemia and common variable immunodeficiency).</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>T-lymphocyte [cell-mediated and humoral] - Complete defects</text>
<code>147</code>
</observationCode>
<description>Administer to persons who have complete cell-mediated or humoral T-lymphocyte defects (e.g., severe combined immunodeficiency [SCID] disease, complete DiGeorge syndrome).</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>T-lymphocyte [cell-mediated and humoral] - Partial defects</text>
<code>148</code>
</observationCode>
<description>Administer to persons who have partial cell-mediated or humoral T-lymphocyte defects (e.g., most patients with DiGeorge syndrome, Wiskott-Aldrich syndrome, ataxia- telangiectasia).</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency</text>
<code>153</code>
</observationCode>
<description>Administer to persons who have a phagocytic function defect (e.g. leukocyte adhesion defect and myeloperoxidase deficiency).</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>HIV/AIDS - Severely immunocompromised</text>
<code>154</code>
</observationCode>
<description>Administer to persons who have HIV/AIDS and are severely immunocompromised [See the CDC general recommendations for a definition of "severely immunocompromised"].</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Transplantation</text>
<code>157</code>
</observationCode>
<description>Administer to persons who have received a transplant.</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Immunosuppressive therapy</text>
<code>158</code>
</observationCode>
<description>Administer to persons who are undergoing immunosuppressive therapy. Immunosuppressive medications include those given to prevent solid organ transplant rejection, human immune mediators like interleukins and colony-stimulating factors, immune modulators like levamisol and BCG bladder-tumor therapy, and medicines like tumor necrosis factor alpha inhibitors and anti-B cell antibodies. </description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance>When immunocompromising therapy is being planned, vaccination should be completed at least 2 weeks before initiation or resumption of therapy.</guidance>
</indication>
<indication>
<observationCode>
<text>Radiation therapy</text>
<code>159</code>
</observationCode>
<description>Administer to persons who are undergoing radiation therapy.</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance>When immunocompromising therapy is being planned, vaccination should be completed at least 2 weeks before initiation or resumption of therapy.</guidance>
</indication>
<indication>
<observationCode>
<text>Active treatement for solid tumors</text>
<code>189</code>
</observationCode>
<description>Administer to persons receiving active treatement for solid tumors</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Active treatement for hematologic malignancies</text>
<code>190</code>
</observationCode>
<description>Administer to persons receiving active treatement for hematologic malignancies</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Receipt of CAR-T-cell therapy</text>
<code>191</code>
</observationCode>
<description>Adminster to persons receiving CAR-T-cell therapy</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>21 days - 4 days</absMinInt>
<minInt>21 days</minInt>
<earliestRecInt>21 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>Y</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 3</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>28 days - 4 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>Y</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>Risk 3-dose Moderna series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>A patients clinical team is best positioned to determine the degree of immune compromise and appropriate timing of vaccination.

Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.</seriesAdminGuidance>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Current evidence suggests that the risk of SARS-CoV-2 reinfection is low in the months after initial infection but may increase with time due to waning immunity. Thus, people with a history of MIS-C or MIS-A should consider delaying vaccination until they have recovered from illness and for 90 days after the date of diagnosis of MIS-C or MIS-A, recognizing that the risk of reinfection and, therefore, the benefit from vaccination, might increase with time following initial infection.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesAdminGuidance>If age 12 through 17 years and Moderna vaccine inadvertently administered instead of Pfizer-BioNTech as the first dose, may administer Moderna vaccine as the second dose (as off-label use, because Moderna vaccine is not authorized in this age group).</seriesAdminGuidance>
<seriesType>Risk</seriesType>
<equivalentSeriesGroups>3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>Yes</productPath>
<seriesGroupName>Increased Risk</seriesGroupName>
<seriesGroup>2</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>2</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication>
<observationCode>
<text>Recipient of a hematopoietic stem cell transplant</text>
<code>004</code>
</observationCode>
<description>Administer to recipients of a hematopoietic stem cell transplant [HSCT] within 2 years of successful transplantation.</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>B-lymphocyte [humoral] - Severe antibody deficiencies</text>
<code>145</code>
</observationCode>
<description>Administer to persons who have severe B-lymphocyte (humoral) - antibody deficiencies (e.g., X-linked agammaglobulinemia and common variable immunodeficiency).</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>T-lymphocyte [cell-mediated and humoral] - Complete defects</text>
<code>147</code>
</observationCode>
<description>Administer to persons who have complete cell-mediated or humoral T-lymphocyte defects (e.g., severe combined immunodeficiency [SCID] disease, complete DiGeorge syndrome).</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>T-lymphocyte [cell-mediated and humoral] - Partial defects</text>
<code>148</code>
</observationCode>
<description>Administer to persons who have partial cell-mediated or humoral T-lymphocyte defects (e.g., most patients with DiGeorge syndrome, Wiskott-Aldrich syndrome, ataxia- telangiectasia).</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency</text>
<code>153</code>
</observationCode>
<description>Administer to persons who have a phagocytic function defect (e.g. leukocyte adhesion defect and myeloperoxidase deficiency).</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>HIV/AIDS - Severely immunocompromised</text>
<code>154</code>
</observationCode>
<description>Administer to persons who have HIV/AIDS and are severely immunocompromised [See the CDC general recommendations for a definition of "severely immunocompromised"].</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Transplantation</text>
<code>157</code>
</observationCode>
<description>Administer to persons who have received a transplant.</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Immunosuppressive therapy</text>
<code>158</code>
</observationCode>
<description>Administer to persons who are undergoing immunosuppressive therapy. Immunosuppressive medications include those given to prevent solid organ transplant rejection, human immune mediators like interleukins and colony-stimulating factors, immune modulators like levamisol and BCG bladder-tumor therapy, and medicines like tumor necrosis factor alpha inhibitors and anti-B cell antibodies. </description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance>When immunocompromising therapy is being planned, vaccination should be completed at least 2 weeks before initiation or resumption of therapy.</guidance>
</indication>
<indication>
<observationCode>
<text>Radiation therapy</text>
<code>159</code>
</observationCode>
<description>Administer to persons who are undergoing radiation therapy.</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance>When immunocompromising therapy is being planned, vaccination should be completed at least 2 weeks before initiation or resumption of therapy.</guidance>
</indication>
<indication>
<observationCode>
<text>Active treatement for solid tumors</text>
<code>189</code>
</observationCode>
<description>Administer to persons receiving active treatement for solid tumors</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Active treatement for hematologic malignancies</text>
<code>190</code>
</observationCode>
<description>Administer to persons receiving active treatement for hematologic malignancies</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Receipt of CAR-T-cell therapy</text>
<code>191</code>
</observationCode>
<description>Adminster to persons receiving CAR-T-cell therapy</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>208; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>208; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>28 days - 4 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>Y</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 3</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>208; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>28 days - 4 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>Y</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>Risk 1-dose Janssen series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>A patients clinical team is best positioned to determine the degree of immune compromise and appropriate timing of vaccination.

Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.</seriesAdminGuidance>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Current evidence suggests that the risk of SARS-CoV-2 reinfection is low in the months after initial infection but may increase with time due to waning immunity. Thus, people with a history of MIS-C or MIS-A should consider delaying vaccination until they have recovered from illness and for 90 days after the date of diagnosis of MIS-C or MIS-A, recognizing that the risk of reinfection and, therefore, the benefit from vaccination, might increase with time following initial infection.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesType>Risk</seriesType>
<equivalentSeriesGroups>3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>Yes</productPath>
<seriesGroupName>Increased Risk</seriesGroupName>
<seriesGroup>2</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>3</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication>
<observationCode>
<text>Recipient of a hematopoietic stem cell transplant</text>
<code>004</code>
</observationCode>
<description>Administer to recipients of a hematopoietic stem cell transplant [HSCT] within 2 years of successful transplantation.</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>B-lymphocyte [humoral] - Severe antibody deficiencies</text>
<code>145</code>
</observationCode>
<description>Administer to persons who have severe B-lymphocyte (humoral) - antibody deficiencies (e.g., X-linked agammaglobulinemia and common variable immunodeficiency).</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>T-lymphocyte [cell-mediated and humoral] - Complete defects</text>
<code>147</code>
</observationCode>
<description>Administer to persons who have complete cell-mediated or humoral T-lymphocyte defects (e.g., severe combined immunodeficiency [SCID] disease, complete DiGeorge syndrome).</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>T-lymphocyte [cell-mediated and humoral] - Partial defects</text>
<code>148</code>
</observationCode>
<description>Administer to persons who have partial cell-mediated or humoral T-lymphocyte defects (e.g., most patients with DiGeorge syndrome, Wiskott-Aldrich syndrome, ataxia- telangiectasia).</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency</text>
<code>153</code>
</observationCode>
<description>Administer to persons who have a phagocytic function defect (e.g. leukocyte adhesion defect and myeloperoxidase deficiency).</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>HIV/AIDS - Severely immunocompromised</text>
<code>154</code>
</observationCode>
<description>Administer to persons who have HIV/AIDS and are severely immunocompromised [See the CDC general recommendations for a definition of "severely immunocompromised"].</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Transplantation</text>
<code>157</code>
</observationCode>
<description>Administer to persons who have received a transplant.</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Immunosuppressive therapy</text>
<code>158</code>
</observationCode>
<description>Administer to persons who are undergoing immunosuppressive therapy. Immunosuppressive medications include those given to prevent solid organ transplant rejection, human immune mediators like interleukins and colony-stimulating factors, immune modulators like levamisol and BCG bladder-tumor therapy, and medicines like tumor necrosis factor alpha inhibitors and anti-B cell antibodies. </description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance>When immunocompromising therapy is being planned, vaccination should be completed at least 2 weeks before initiation or resumption of therapy.</guidance>
</indication>
<indication>
<observationCode>
<text>Radiation therapy</text>
<code>159</code>
</observationCode>
<description>Administer to persons who are undergoing radiation therapy.</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance>When immunocompromising therapy is being planned, vaccination should be completed at least 2 weeks before initiation or resumption of therapy.</guidance>
</indication>
<indication>
<observationCode>
<text>Active treatement for solid tumors</text>
<code>189</code>
</observationCode>
<description>Administer to persons receiving active treatement for solid tumors</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Active treatement for hematologic malignancies</text>
<code>190</code>
</observationCode>
<description>Administer to persons receiving active treatement for hematologic malignancies</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Receipt of CAR-T-cell therapy</text>
<code>191</code>
</observationCode>
<description>Adminster to persons receiving CAR-T-cell therapy</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 208; 210; 211; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>Risk 3-dose mRNA series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>A patients clinical team is best positioned to determine the degree of immune compromise and appropriate timing of vaccination.

Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.</seriesAdminGuidance>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Current evidence suggests that the risk of SARS-CoV-2 reinfection is low in the months after initial infection but may increase with time due to waning immunity. Thus, people with a history of MIS-C or MIS-A should consider delaying vaccination until they have recovered from illness and for 90 days after the date of diagnosis of MIS-C or MIS-A, recognizing that the risk of reinfection and, therefore, the benefit from vaccination, might increase with time following initial infection.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesType>Risk</seriesType>
<equivalentSeriesGroups>3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>Yes</productPath>
<seriesGroupName>Increased Risk</seriesGroupName>
<seriesGroup>2</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>4</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication>
<observationCode>
<text>Recipient of a hematopoietic stem cell transplant</text>
<code>004</code>
</observationCode>
<description>Administer to recipients of a hematopoietic stem cell transplant [HSCT] within 2 years of successful transplantation.</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>B-lymphocyte [humoral] - Severe antibody deficiencies</text>
<code>145</code>
</observationCode>
<description>Administer to persons who have severe B-lymphocyte (humoral) - antibody deficiencies (e.g., X-linked agammaglobulinemia and common variable immunodeficiency).</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>T-lymphocyte [cell-mediated and humoral] - Complete defects</text>
<code>147</code>
</observationCode>
<description>Administer to persons who have complete cell-mediated or humoral T-lymphocyte defects (e.g., severe combined immunodeficiency [SCID] disease, complete DiGeorge syndrome).</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>T-lymphocyte [cell-mediated and humoral] - Partial defects</text>
<code>148</code>
</observationCode>
<description>Administer to persons who have partial cell-mediated or humoral T-lymphocyte defects (e.g., most patients with DiGeorge syndrome, Wiskott-Aldrich syndrome, ataxia- telangiectasia).</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency</text>
<code>153</code>
</observationCode>
<description>Administer to persons who have a phagocytic function defect (e.g. leukocyte adhesion defect and myeloperoxidase deficiency).</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>HIV/AIDS - Severely immunocompromised</text>
<code>154</code>
</observationCode>
<description>Administer to persons who have HIV/AIDS and are severely immunocompromised [See the CDC general recommendations for a definition of "severely immunocompromised"].</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Transplantation</text>
<code>157</code>
</observationCode>
<description>Administer to persons who have received a transplant.</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Immunosuppressive therapy</text>
<code>158</code>
</observationCode>
<description>Administer to persons who are undergoing immunosuppressive therapy. Immunosuppressive medications include those given to prevent solid organ transplant rejection, human immune mediators like interleukins and colony-stimulating factors, immune modulators like levamisol and BCG bladder-tumor therapy, and medicines like tumor necrosis factor alpha inhibitors and anti-B cell antibodies. </description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance>When immunocompromising therapy is being planned, vaccination should be completed at least 2 weeks before initiation or resumption of therapy.</guidance>
</indication>
<indication>
<observationCode>
<text>Radiation therapy</text>
<code>159</code>
</observationCode>
<description>Administer to persons who are undergoing radiation therapy.</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance>When immunocompromising therapy is being planned, vaccination should be completed at least 2 weeks before initiation or resumption of therapy.</guidance>
</indication>
<indication>
<observationCode>
<text>Active treatement for solid tumors</text>
<code>189</code>
</observationCode>
<description>Administer to persons receiving active treatement for solid tumors</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Active treatement for hematologic malignancies</text>
<code>190</code>
</observationCode>
<description>Administer to persons receiving active treatement for hematologic malignancies</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Receipt of CAR-T-cell therapy</text>
<code>191</code>
</observationCode>
<description>Adminster to persons receiving CAR-T-cell therapy</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>210; 211; 212</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge/>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>210; 211; 212</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>28 days - 4 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 3</doseNumber>
<age>
<absMinAge/>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>210; 211; 212</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>28 days - 4 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>2-dose AstraZeneca Series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance/>
<seriesType>Evaluation Only</seriesType>
<equivalentSeriesGroups/>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>No</productPath>
<seriesGroupName>WHO-Authorized </seriesGroupName>
<seriesGroup>3</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>1</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication/>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval/>
<allowableInterval/>
<preferableVaccine/>
<allowableVaccine>
<vaccineType>COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL</vaccineType>
<cvx>210</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>8 weeks</minInt>
<earliestRecInt>8 weeks</earliestRecInt>
<latestRecInt>12 weeks</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine/>
<allowableVaccine>
<vaccineType>COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL</vaccineType>
<cvx>210</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>2-dose BIBP Sinopharm Series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance/>
<seriesType>Evaluation Only</seriesType>
<equivalentSeriesGroups/>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>No</productPath>
<seriesGroupName>WHO-Authorized </seriesGroupName>
<seriesGroup>3</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>2</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication/>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval/>
<allowableInterval/>
<preferableVaccine/>
<allowableVaccine>
<vaccineType>COVID-19 IV Non-US Vaccine (BIBP, Sinopharm)</vaccineType>
<cvx>510</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>3 weeks</minInt>
<earliestRecInt>3 weeks</earliestRecInt>
<latestRecInt>4 weeks</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine/>
<allowableVaccine>
<vaccineType>COVID-19 IV Non-US Vaccine (BIBP, Sinopharm)</vaccineType>
<cvx>510</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>2-dose CoronaVac Sinovac Series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance/>
<seriesType>Evaluation Only</seriesType>
<equivalentSeriesGroups/>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>No</productPath>
<seriesGroupName>WHO-Authorized </seriesGroupName>
<seriesGroup>3</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>3</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication/>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval/>
<allowableInterval/>
<preferableVaccine/>
<allowableVaccine>
<vaccineType>COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)</vaccineType>
<cvx>511</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>2 weeks</minInt>
<earliestRecInt>2 weeks</earliestRecInt>
<latestRecInt>4 weeks</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine/>
<allowableVaccine>
<vaccineType>COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)</vaccineType>
<cvx>511</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
</antigenSupportingData>
